Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

0.6569 -0.0231 (-3.40%)
Streaming Delayed Price Updated: 12:02 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
From Xilio Therapeutics, Inc.
Via GlobeNewswire
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via GlobeNewswire
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.